Alzheimer’s disease may be caused by the abnormal build-up of proteins around brain cells. FAU researchers including Gregg Fields, executive director of FAU’s Institute for Human Health and Disease Intervention (I-Health), and Delray Medical Center have joined forces to conduct a medical trial of a method to combat this build-up using ultrasound waves.

The clinical trial is designed to evaluate the safety and efficacy of Insightec’s ExAblate Model 4000 Type 2.0 System as a tool for disrupting the blood-brain barrier in probable Alzheimer’s patients.  “The treatment … represents a significant advancement for potential drug delivery and treatment of Alzheimer’s disease and other neurological disorders,” said Fields.

• Gregg Fields